.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Hepatoprotective regimens during chemotherapy are common in clinical practice. Clinicians often prescribe S-adenosylmethionine (SAMe) to manage liver injury. However, recent research highlights potential risks regarding SAMe breast cancer outcomes. A retrospective cohort study evaluated 1013 women treated for primary breast cancer. Therefore, doctors must balance hepatoprotection with oncologic safety.
The study found that SAMe exposure correlates with shorter overall survival. Moreover, disease-free survival rates were lower in patients receiving SAMe. Using ROC analysis, the team identified a critical threshold for exposure duration. Patients receiving more than four cycles of SAMe faced significant clinical risks. Consequently, high exposure levels more than doubled the hazard for death and disease recurrence.
Why does prolonged exposure impact SAMe breast cancer outcomes negatively? Transcriptomic data suggest that SAMe acts as a universal methyl donor. Increased intratumoral SAMe levels promote specific methylation signals like m6A, m5C, and m7G. Additionally, high METTL3 and METTL14 expression levels may drive tumor progression. These epigenetic changes potentially foster chemoresistance within the tumor microenvironment. Therefore, the biochemical role of SAMe might inadvertently support tumor survival during chemotherapy.
Doctors should reconsider long-term SAMe use for hepatoprotection during chemotherapy. Instead, they might explore alternative regimens that do not interfere with tumor epigenetics. Furthermore, monitoring the duration of supplement use is essential for patient safety. While liver protection remains a priority, maintaining oncologic efficacy is paramount. Further prospective studies will clarify these metabolic interactions in various cancer subtypes.
Prolonged exposure to SAMe, specifically beyond four cycles, is associated with shorter survival and a higher likelihood of cancer recurrence due to epigenetic alterations.
Yes, higher levels of intratumoral SAMe correlate with increased METTL3 and METTL14 expression, which drive RNA methylation pathways linked to poorer prognosis.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study warns that prolonged S-adenosylmethionine (SAMe) use during breast cancer chemotherapy may reduce survival and treatment response....
4 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
